JP2012513467A5 - - Google Patents

Download PDF

Info

Publication number
JP2012513467A5
JP2012513467A5 JP2011543601A JP2011543601A JP2012513467A5 JP 2012513467 A5 JP2012513467 A5 JP 2012513467A5 JP 2011543601 A JP2011543601 A JP 2011543601A JP 2011543601 A JP2011543601 A JP 2011543601A JP 2012513467 A5 JP2012513467 A5 JP 2012513467A5
Authority
JP
Japan
Prior art keywords
resistant
bacterium
pharmaceutical composition
clostridium difficile
antibiotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011543601A
Other languages
English (en)
Japanese (ja)
Other versions
JP5670914B2 (ja
JP2012513467A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/068747 external-priority patent/WO2010075215A1/en
Publication of JP2012513467A publication Critical patent/JP2012513467A/ja
Publication of JP2012513467A5 publication Critical patent/JP2012513467A5/ja
Application granted granted Critical
Publication of JP5670914B2 publication Critical patent/JP5670914B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011543601A 2008-12-22 2009-12-18 グラム陽性菌感染症を処置するための新規抗菌剤 Expired - Fee Related JP5670914B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13987508P 2008-12-22 2008-12-22
US61/139,875 2008-12-22
PCT/US2009/068747 WO2010075215A1 (en) 2008-12-22 2009-12-18 Novel antibacterial agents for the treatment of gram positive infections

Publications (3)

Publication Number Publication Date
JP2012513467A JP2012513467A (ja) 2012-06-14
JP2012513467A5 true JP2012513467A5 (enExample) 2013-10-03
JP5670914B2 JP5670914B2 (ja) 2015-02-18

Family

ID=41718893

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011543601A Expired - Fee Related JP5670914B2 (ja) 2008-12-22 2009-12-18 グラム陽性菌感染症を処置するための新規抗菌剤

Country Status (26)

Country Link
US (3) US8507647B2 (enExample)
EP (2) EP2674437A1 (enExample)
JP (1) JP5670914B2 (enExample)
KR (1) KR101717795B1 (enExample)
CN (1) CN102325787B (enExample)
AR (1) AR074833A1 (enExample)
AU (1) AU2009330245C1 (enExample)
BR (1) BRPI0923567A2 (enExample)
CA (1) CA2747965C (enExample)
CY (1) CY1114883T1 (enExample)
DK (1) DK2379580T3 (enExample)
ES (1) ES2442167T3 (enExample)
HR (1) HRP20131170T1 (enExample)
IL (1) IL213638A0 (enExample)
MX (1) MX2011006803A (enExample)
NZ (1) NZ594019A (enExample)
PL (1) PL2379580T3 (enExample)
PT (1) PT2379580E (enExample)
RS (1) RS53152B (enExample)
RU (1) RU2512396C2 (enExample)
SG (1) SG172299A1 (enExample)
SI (1) SI2379580T1 (enExample)
SM (1) SMT201400037B (enExample)
TW (1) TWI444198B (enExample)
WO (1) WO2010075215A1 (enExample)
ZA (1) ZA201104693B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012162567A1 (en) * 2011-05-26 2012-11-29 Cubist Pharmaceuticals, Inc. Cb-183,315 compositions and related methods
US10377699B2 (en) * 2013-11-06 2019-08-13 The University Of Hong Kong Daptomycin analogues and a method for the preparation of daptomycin or a daptomycin analogue
WO2015172047A1 (en) * 2014-05-08 2015-11-12 Merck Sharp & Dohme Corp. Cyclic peptide compounds and related methods, salts and compositions
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
SMT202000249T1 (it) * 2016-04-22 2020-07-08 Astrazeneca Ab Inibitori di mcl1 macrociclici per il trattamento di cancro
US10098890B2 (en) 2016-10-29 2018-10-16 Cipla Limited Stable carfilzomib formulations
IT201600127655A1 (it) * 2016-12-16 2018-06-16 Gnosis Spa Processo per la purificazione di antibiotici lipopolipeptidici
US10072045B1 (en) 2017-06-26 2018-09-11 Ramapo Pharmaceuticals, Inc. Antibacterial lipopeptides and methods for their preparation and use
US10526343B2 (en) 2018-03-26 2020-01-07 University Of Sharjah Heterocyclic systems and pharmaceutical applications thereof
RU2762182C1 (ru) * 2020-12-08 2021-12-16 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт по изысканию новых антибиотиков имени Г.Ф. Гаузе" Гауземицины А и В - гликолипопептидные антибактериальные антибиотики и способ их получения

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
USRE32333E (en) 1978-10-16 1987-01-20 Eli Lilly And Company A-21978 Antibiotics and process for their production
USRE32455E (en) 1978-10-16 1987-07-07 Eli Lilly And Company A-21978 antibiotics and process for their production
CA1195983A (en) 1982-02-27 1985-10-29 Graham Walker Antibacterial 1-normon-2-yl thiazoles and - oxazoles
US4399067A (en) 1982-05-21 1983-08-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4396543A (en) 1982-05-21 1983-08-02 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
IL68700A0 (en) * 1982-05-21 1983-09-30 Lilly Co Eli Improvements relating to a-21978c cyclic peptide derivatives and their production
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
DD238068A5 (de) 1984-10-09 1986-08-06 ���@�����@�K@�������k�� Verfahren zur herstellung von derivaten der cyclopeptidantibiotika a-21978 c
CA1315229C (en) 1987-06-10 1993-03-30 Eli Lilly And Company Chromatographic purification process
US5039660A (en) 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
EP0460882B1 (en) 1990-06-07 1996-07-24 Eli Lilly And Company Lipopeptide deacylase
JPH09504512A (ja) 1993-08-13 1997-05-06 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 抗菌活性、抗マイコプラズマ活性、抗真菌類活性および除草活性を有するモン酸aおよびcの誘導体
DE4411025A1 (de) 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
EP1854877B1 (en) 1996-03-08 2012-02-08 Astellas Pharma Inc. Process for the deacylation of cyclic lipopeptides
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
DK1115417T3 (da) 1998-09-25 2006-07-31 Cubist Pharm Inc Anvendelse af daptomycin
CN1181367C (zh) 1999-11-03 2004-12-22 惠特克公司 多光纤阵列的光电模块
IL150223A0 (en) 1999-12-15 2002-12-01 Cubist Pharm Inc Lipopeptides and pharmaceutical compositions containing the same
CN1423656A (zh) 1999-12-15 2003-06-11 卡比斯特制药公司 作为抗菌剂的脂肽
CA2394313A1 (en) 1999-12-15 2001-06-21 Cubist Pharmaceuticals, Inc. Novel lipopeptides as antibacterial agents
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
EP1423137B1 (en) 2001-08-06 2009-04-29 Cubist Pharmaceuticals, Inc. Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
JP2008519848A (ja) * 2004-11-12 2008-06-12 キュービスト ファーマシューティカルズ, インコーポレイテッド 抗感染性リポペプチド

Similar Documents

Publication Publication Date Title
RU2011130278A (ru) Новые противобактериальные средства для лечения грамположительных инфекций
Szczuka et al. Antimicrobial activity of tigecycline alone or in combination with rifampin against Staphylococcus epidermidis in biofilm
CN108823124B (zh) 一株对革兰阳性耐药菌具有广谱抗菌活性的表皮葡萄球菌及其筛选方法和应用
Marsilio et al. Coagulase-positive and coagulase-negative staphylococci animal diseases
JP2017519730A5 (enExample)
EP2822582B1 (en) Multivalent vaccine protection from staphylococcus aureus infection
RU2004118716A (ru) Лечение инфекции, вызываемой микроорганизмами
JP2017533177A5 (enExample)
MXPA06000691A (es) Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables y uso de las mismas.
KR20120038698A (ko) 항생제 저항성 포도상구균(mrsa)억제 유산균 바이셀라 비리데센스
JP2024009968A5 (enExample)
WO2013041663A3 (de) Modifizierte apidaecinderivate als antibiotische peptide
MX2007009059A (es) Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables, y uso de los mismos.
CN108420814A (zh) 一种nps-2143用于抗菌的新用途
Bell et al. Antimicrobial activity and spectrum of daptomycin: results from the surveillance program in Australia and New Zealand (2008)
CN104971342A (zh) 一种抗甲氧西林耐药的金黄色葡萄球菌的药物组合物
Leite et al. N-acetylcysteine and vancomycin alone and in combination against staphylococci biofilm
Sibanda et al. In vitro antibacterial activities of crude extracts of Garcinia kola seeds against wound sepsis associated Staphylococcus strains
Hussain et al. Resistance pattern of 3rd generation cephalosporins
Jung et al. Antibacterial activity of LCB01-0062, a novel oxazolidinone
WO2009124086A3 (en) Antibacterial drug for treatment of staphylococcus aureus and other gram-positive bacterial infections
Mokrozub et al. Antistaphylococcal action of lacto-and bifidobacteria and interleukin-2
CN109620827B (zh) 杂环丙烯酮类化合物作为抗菌剂的用途
CN115804779B (zh) 治疗细菌感染的苯并噁嗪噁唑烷酮类化合物
Park et al. Chemical optimization and derivatization of micrococcin p2 to target multiple bacterial infections: new antibiotics from thiopeptides